Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth noting that PARP inhibitors have precedence of failure in earlier trials in Urothelial Carcinoma. The data from ATLANTIS, BAYOU, and Meet-URO12 Trials in Urothelial Cancer were presented at ASCO GU 2022.
Lynparza in combination with Durvalumab fails to impress in platinum ineligible metastatic Urothelial Carcinoma patients: Data from BAYOU trial
A...
